WO2017086385A8 - Par1阻害をメカニズムとする異所性骨化の治療薬剤 - Google Patents
Par1阻害をメカニズムとする異所性骨化の治療薬剤 Download PDFInfo
- Publication number
- WO2017086385A8 WO2017086385A8 PCT/JP2016/084101 JP2016084101W WO2017086385A8 WO 2017086385 A8 WO2017086385 A8 WO 2017086385A8 JP 2016084101 W JP2016084101 W JP 2016084101W WO 2017086385 A8 WO2017086385 A8 WO 2017086385A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- par1
- blocking
- ectopic ossification
- fop
- treatment drug
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
【課題】FOP患者における病態メカニズムをより明らかにするとともに,得られた知見を活かした新たな治療薬や治療方法,診断方法等の開発。 【解決手段】発明者らは,FOPにおいて,外傷等による炎症をきっかけとして生じる異所性骨化が,PAR1を介して起こっているという新たな知見を見出した。発明者らはこの知見から,PAR1を阻害することにより,FOPの異所性骨化を抑制することを特徴とする薬剤等にかかる発明を完成させたものである。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16866386.2A EP3378490B1 (en) | 2015-11-20 | 2016-11-17 | Ectopic ossification treatment drug having mechanism for blocking par1 |
US15/776,152 US20200253942A1 (en) | 2015-11-20 | 2016-11-17 | Therapeutic drug for ectopic ossification having mechanism to inhibit par1 |
JP2017551922A JP6873410B2 (ja) | 2015-11-20 | 2016-11-17 | Par1阻害をメカニズムとする異所性骨化の治療薬剤 |
US17/106,565 US20210161872A1 (en) | 2015-11-20 | 2020-11-30 | Therapeutic drug for ectopic ossification having mechanism to inhibit par1 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015-228232 | 2015-11-20 | ||
JP2015228232 | 2015-11-20 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/776,152 A-371-Of-International US20200253942A1 (en) | 2015-11-20 | 2016-11-17 | Therapeutic drug for ectopic ossification having mechanism to inhibit par1 |
US17/106,565 Division US20210161872A1 (en) | 2015-11-20 | 2020-11-30 | Therapeutic drug for ectopic ossification having mechanism to inhibit par1 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2017086385A1 WO2017086385A1 (ja) | 2017-05-26 |
WO2017086385A8 true WO2017086385A8 (ja) | 2018-01-18 |
Family
ID=58718886
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/084101 WO2017086385A1 (ja) | 2015-11-20 | 2016-11-17 | Par1阻害をメカニズムとする異所性骨化の治療薬剤 |
Country Status (4)
Country | Link |
---|---|
US (2) | US20200253942A1 (ja) |
EP (1) | EP3378490B1 (ja) |
JP (1) | JP6873410B2 (ja) |
WO (1) | WO2017086385A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020135812A1 (en) | 2018-12-29 | 2020-07-02 | Shanghai United Imaging Intelligence Co., Ltd. | Systems and methods for ossification center detection and bone age assessment |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140378502A1 (en) * | 2011-05-12 | 2014-12-25 | UNIVERSITé LAVAL | Par1 Inhibitors for Use in the Treatment or Prevention of Paramyxoviridae Infections |
WO2015054718A1 (en) * | 2013-10-18 | 2015-04-23 | The University Of Sydney | Bone formation |
JP6601687B2 (ja) * | 2014-03-31 | 2019-11-06 | 大日本住友製薬株式会社 | 進行性骨化性線維異形成症の予防剤及び治療剤 |
-
2016
- 2016-11-17 JP JP2017551922A patent/JP6873410B2/ja active Active
- 2016-11-17 WO PCT/JP2016/084101 patent/WO2017086385A1/ja active Application Filing
- 2016-11-17 EP EP16866386.2A patent/EP3378490B1/en active Active
- 2016-11-17 US US15/776,152 patent/US20200253942A1/en not_active Abandoned
-
2020
- 2020-11-30 US US17/106,565 patent/US20210161872A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20210161872A1 (en) | 2021-06-03 |
EP3378490A1 (en) | 2018-09-26 |
EP3378490B1 (en) | 2020-07-15 |
WO2017086385A1 (ja) | 2017-05-26 |
JPWO2017086385A1 (ja) | 2018-09-06 |
US20200253942A1 (en) | 2020-08-13 |
EP3378490A4 (en) | 2019-07-31 |
JP6873410B2 (ja) | 2021-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017500493A1 (en) | Combination therapy | |
EP3231436A4 (en) | Pharmaceutical composition for prevention or treatment of metabolic disease, comprising bacteroides acidifaciens as effective ingredient | |
IL272601A (en) | Pharmaceutical preparations for the treatment of ophthalmic conditions | |
ZA201805407B (en) | Composition for the prevention or treatment of neurodegenerative diseases. | |
PL3268029T3 (pl) | Leczenie pacjentów z cukrzycą typu 2 | |
ZA202002993B (en) | Compounds for the treatment of neuromuscular disorders | |
MX2020001256A (es) | Compuestos para la prevencion y el tratamiento de trastornos medicos y usos de los mismos. | |
WO2015001541A3 (en) | Pharmaceutical film composition | |
WO2017086385A8 (ja) | Par1阻害をメカニズムとする異所性骨化の治療薬剤 | |
SG11201707467PA (en) | Treatment of type 2 diabetes mellitus patients | |
HK1259373A1 (zh) | 用於治療糖尿病的藥物製劑 | |
WO2016020408A3 (en) | Compounds for preventing ototoxicity | |
IL256919A (en) | Pharmaceutical compositions useful for the treatment of tissue damage | |
MX2018006631A (es) | Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas. | |
IL251392B (en) | Transformed aromatic compounds and their pharmaceutical preparations for the prevention and treatment of diabetes | |
PL3217975T3 (pl) | Zastosowanie skutecznych pod względem immunomodulacji kompozycji do immunoterapeutycznego leczenia pacjentów z białaczką szpikową | |
MA40065A (fr) | N, n-bis-2-mercaptoéthyle isophtalamide pour le traitement de la maladie de parkinson | |
EP3189846A4 (en) | Pharmaceutical composition for prevention or treatment neuro-inflammation or neurodegenerative diseases comprising Portulaca grandiflora Hook. extracts or fractions thereof | |
MX2015001677A (es) | Composicion con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patologia del sistema nervioso central, y su metodo de fabricacion. | |
IL287529B (en) | A pharmaceutical combination that includes trazodone for the treatment of neuropathic pain | |
PT3724173T (pt) | Compostos para o tratamento de distúrbios neuromusculares | |
AU2016905281A0 (en) | Pharmaceutical composition for treatment of an eye disease or condition | |
AU2016904360A0 (en) | Pharmaceutical composition for treatment of an eye disease or condition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16866386 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2017551922 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2016866386 Country of ref document: EP |